X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
Delta-Fly (ubenimex) is a Aminopeptidase N inhibitor. It is being evaluated in phase 3 clinical trials in combination with afatinib for the treatment of stage III/IV non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutation.
Lead Product(s): ubenimex,Afatinib
Therapeutic Area: Oncology Product Name: DFP-14323
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2024
Details:
The NCI-MATCH, a precision medicine study launched by the ECOG-ACRIN Cancer Research Group and the National Cancer Institute, has found that many patients’ tumors bear genetic abnormalities that can be targeted with existing drugs—approved or experimental.
Lead Product(s): Afatinib
Therapeutic Area: Oncology Product Name: Gilotrif
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020
Details:
Sequential Gilotrif® (afatinib) and osimertinib contributed to a median overall survival (OS) of nearly four years among U.S. patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer and the common resistance mutation, T790M.
Lead Product(s): Afatinib,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Gilotrif
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
